We are live on ! Find out more
WHWK

Whitehawk Therapeutics

75 hedge funds and large institutions have $192M invested in Whitehawk Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

44,200% more call options, than puts

Call options by funds: $1.33M | Put options by funds: $3K

117% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 6

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

10% more funds holding

Funds holding: 6875 (+7)

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

9.1% less ownership

Funds ownership: 71.69%62.59% (-9.1%)

10% less capital invested

Capital invested by funds: $212M → $192M (-$20.3M)

Holders
75
Holders Change
+7
Holders Change %
+10.29%
% of All Funds
1.2%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
13
Increased
20
Reduced
22
Closed
6
Calls
$1.33M
Puts
$3K
Net Calls
+$1.33M
Net Calls Change
-$1.59M

WHWK Hedge Fund Activity: Q4 2022 in Review

75 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q4 2022, worth a combined $192M — down 9.6% from $212M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new WHWK positions and 6 closed out — a net gain of 7 holders — while 20 added to existing stakes and 22 trimmed.

The largest buyer was Ally Bridge Group, adding an estimated $6.64M. The largest seller was Point72 Asset Management, cutting an estimated $6.54M.

  • 75 institutional investors held Whitehawk Therapeutics (WHWK) as of Q4 2022, up from 68 in Q3 2022.
  • Funds reported $192M of Whitehawk Therapeutics stock for Q4 2022, down 9.6% quarter-over-quarter.
  • 13 funds opened new Whitehawk Therapeutics positions in Q4 2022 and 6 closed out, a net change of +7 holders.
  • The largest Whitehawk Therapeutics buyer in Q4 2022 was Ally Bridge Group, an estimated $6.64M added.
  • The largest Whitehawk Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $6.54M sold.

Based on aggregated 13F filings for Q4 2022.